STATEMENT OF WORK

• Document Type: CREST
• Collection: STARGATE
• Document Number (FOIA) /ESDN (CREST): CIA-RDP96-00788R001500110030-2
• Release Decision: RIFPUB
• Original Classification: S
• Document Page Count: 6
• Document Creation Date: November 4, 2016
• Document Release Date: September 6, 2000
• Sequence Number: 30
• Content Type: CONT

Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110030-2
1. (U) GENERAL
1.1 (S/CL-3/NOFORN) The objective of this effort is to
investigate a particular aspect of the psychoenergetic
phenomena known as remote viewing that has potential military
intelligence application. Coordinate Remote Viewing (CRV) is a
staged technique which utilizes coordinates to facilitate
acquisition of a remote viewing target.
1.2 (S/CL-3/NOFORN) Major goals are the determination if
CRV technology can be successfully transferred to INSCOM
personnel with a corresponding increase in the reliability of a
remote viewer.
2. (U) SPECIFIC TASK
2.1 (S/CL-3/NOFORN) Train army person in CRV Stages I and
2.1.1 (S/CL-3/NOFORN) Initiate training at the highest
skill level (CRV Stage) of the trainee.
2.1.2 (S/CL-3/NOFORN) Training for each CRV stage will
normally be divided into (number and duration) working
sessions. The session dates will be mutually agreed to by SRI
and INSCOM.
2.1.3 (S/CL-3/NOFORN) After successful completion of each
CRV Stage, schedule the trainee to begin next CRV Stage.
2.2 (U) Determine the potential of the trainee for
further training.
3. (U) SECURITY
Military security requirements in the performance of this
contract shall be maintained in accordance with DD Form 254
attached hereto. The highest classification involved in the
performance of this contract is SECRET- NO FOREIGN
DISSEMINATION.
4. (U) DELIVERABLES: The contractor will provide the
following.
4.1 (S/CL-3/NOFORN) State-of-the-Art CRV training.
CENTER IAHI
CLASSIFIED BY: CDR, INSCOM
DECL: OADR
Approved For Release 20d }%f'M.R
6AOIi1500110030-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788ROO1500110030-2
4.2 (U) Progress report (2 copies): Written evaluation
of the trainee's progress within 10 days after the completion
of each training block.
4.3 (U) Final report:
4.3.1 (U) A final report in three copies will be
furnished within 30 days after completion of each training
stage.
4.3.2 (U) Report will include a summary of the training
presented; an evaluation of the trainee's ability to understand
the training; and a summary of the trainee's accomplishments
during the training period.
4.3.3 (S/CL-3/NOFORN) Report should also include an
evaluation of the trainee's future remote viewing capabilities,
and a recommendation concerning further training.
5. (S/CL-3/NOFORN) POST TRAINING ACCESS: After the
completion of each CRV training stage personnel involved in the
training program will have reasonable access to INSCOM
personnel trained to assist in further evaluation of CRV.
6. (U) SPECIAL REQUIREMENTS
6.1 (U) Use of human subjects
(a) (U) The following definitions are used:
(1) (U) At risk means that the human subject may be
exposed to the possibility of harm - physical, biological,
psychological, sociological, or other as a consequence of an
act or omission that goes beyond the application of those
established and accepted methods or procedures which are in his
best interests, or that increases ordinary risks of daily life,
including the recognized risks inherent in his chosen
occupation or field of service.
(2) (U) Human subject means any human being who,
knowingly or unknowingly, is subjected to an act or omission,
whether at risk or not, the object of which is to contribute to
knowledge to be gained as a part of work to be performed under
the scope of this contract.
(b) (U) The contractor, before undertaking to perform
any study involving human subjects, whether at risk or not,
shall insure that the following minimum conditions are complied
with:
ow PM C E
a
Approved For Release 2001/04@F6-00788RO01500110030-2
NOWT RELE IftE TO FOREIGN NATIONALS
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110030-2
U CL S!
(1) (U) The proposed study has been reviewed and
approved by a committee meeting the requirements set forth in
Chapter 46 of Title 45 of the Code of Federal Regulations.
(2) (U) The number of human subjects used will be
kept to the minimum number that will reasonably achieve the
required results.
(3) (U) The study must be such as to contribute
significantly to scientific knowledge and have reasonable
prospects of yielding important results essential to an Army
research program.
(4) (U) The study will be conducted only by persons
possessing the requisite scientific qualifications. The
highest degree of skill and care will be required during all
stages of study of persons who conduct or assist in the study.
(5) (U) The subject will be informed that at any time
during the course of his participation he has the right to
revoke his consent and withdraw from participation without
prejudice to himself.
(6) (U) Participation by subjects will be immediately
terminated if it subsequently appears that the risk to the
subjects is significantly greater than anticipated at the time
review and approval was granted.
(7) (U) There shall be no greater intrusion into the
privacy of the human subject than is absolutely necessary for
the conduct of the study involved. Except for the submission
of reports and other data required by this contract, any
information obtained about human subjects as a result of
participation shall be held as confidential. as the law allow.
(8) (U) The study will be conducted so as to avoid
all unnecessary physical or mental suffering or injury.
(9) (U) No study will be conducted if there is any
inherent reason to believe that death or disabling injury is
likely to occur. Sufficient animal or laboratory experiments,
or other evaluations, must have been completed to give
assurance of acceptable risks prior to the use of human
subjects.
(10) (U) The degree of risk to be taken will never
exceed that which is justified by the benefit to the subject
and/or the humanitarian importance of the knowledge to be
gained.
3
Approved For Release 2001/04/0 :00788R001500110030-2
 Approved For Release 2001
P96-00788R001 500110030-2
(11) (U) A physician will be responsible for the
medical. care of subjects. Even if not the project leader, the
physician will have authority to terminate the study at any
time that he believes death, injury or harm is likely to result.
(12) (U) Proper preparations will be made, and
adequate facilities provided to protect the subject against all
foreseeable possibilities of injury, disability or death. This
includes, but is not limited to, hospitalization and medical
treatment as may be required. In addition, all apparatus and
instruments necessary to deal with likely emergency situations
will be available.
(13) (U) Human subjects will have no physical or
mental conditions which will make participation more hazardous
for them than it would be for normal healthy persons, unless
such condition is a necessary prerequisite for the particular
study involved. In any such case, the use of human subjects
with such pre-existing conditions must have been specifically
described and justified in the scope of the work to be
performed under this contract.
(14) (U) The scientifically qualified person
conducting the study, and each member of his research team,
will be prepared to terminate the subject's participation at
any stage if he has reason to believe, in the exercise of the
good faith, superior skill, and careful judgment required of
hiin, that continuation is likely to result in injury,
disability, or death to the human subject.
(c) (U) The contractor, before permitting any person
to participate as a human subject, whether at risk or not,
shall insure that the following minimum conditions are complied
with:
(1) (U) Legally effective informed consent will be
obtained by adequate and appropriate methods in accordance with
the provisions of this clause.
(2) (U) All consent must be voluntary. It must be
the knowing consent of the individual or his legally authorized
representative, so situated as to be able to exercise free
power of choice without there having been any use of force,
fraud, deceit, duress, constraint, coercion, or lawful or
improper inducement. The elements of information necessary to
such consent include:
(i) (U) A fair explanation of the procedures to be
followed, and their purposes, including identification of any
procedures which are experimental.
Approved For Release 2001/04/
-00788R001 500110030-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110030-2
UNCLASSIFIED
(ii) (U) A description of any attendant discomforts
or risks reasonably to be anticipated.
(iii) (U) A description of any benefits reasonably to
be anticipated.
(iv) (U) A disclosure of any appropriate alternative
procedures that might be advantageous to the subject.
(v) (U) An offer to answer any questions concerning
the procedure.
(vi) (U) An instruction that the subject is free to
revoke his consent and to discontinue participation at any time
without prejudice to himself.
(d) (U) Exculpatory language through which the
subject is made to waive, or appear to waive, any of his legal
rights, including any release from liability for negligence, is
prohibited.
(e) (U) Prior consent by a subject or his legally
authorized representative shall be obtained in all, cases. Such
consent shall be in writing whenever it is reasonably possible
to do so. The consent form may be read to the subject or his
legally authorized representative, but in any event he or his
legally authorized representative must be given adequate
opportunity to read it and to ask questions they might have.
This consent form should then be signed by the subject or his
legally authorized representative and by a witness not directly
involved in the study. Oral consent may be used only when it
has been specifically described and justified in the scope of
the work to be performed under this contract or approved in
writing by the contracting officer. When so authorized and
used, oral consent is subject to all the same standards as
apply to written consent, except that the signature of the
subject or his legally authorized representative is not
required.
(f) (U) Prior to conduct of the. study, the contractor
shall submit for approval to the contracting officer's
representative a detailed description of the means by which
informed consent will be obtained, to include any forms to be
used. Upon completion of the study, the contractor will submit
to the contracting officer's representative a detailed report
demonstrating compliance with paragraph (c), to include copies
of the written consent if such was obtained.
I.fl
5
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110030-2
 Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110030-2
UNCLASSIFIED
(g) (U) The contractor shall not undertake to conduct
either the clinical pharmacology or clinical trails of an
investigational drug unless this contract contains the clause
entitled "Clinical Study of Investigational Drugs."
(h) (U) Prisoners of war will not be used under any
circumstances.
6.2 (U) DoD Directive 5240.1-R governing experimentation
on human subjects. will be followed by the contactor. Informed
consent of all subjects will be obtained in writing in
accordance with the guidelines issued by the Department of
Health, Education and Welfare. All persons participating as
human subjects, as defined in paragraph 6.1 above shall be
known to possess the abilities and qualities which will be
observed and analyzed during the conduct of this contract.
6
Approved For Release 2001/04;,
6-00788R001 500110030-2